<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039177</url>
  </required_header>
  <id_info>
    <org_study_id>ERAS-007-03</org_study_id>
    <nct_id>NCT05039177</nct_id>
  </id_info>
  <brief_title>A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies</brief_title>
  <acronym>HERKULES-3</acronym>
  <official_title>A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasca, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasca, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination&#xD;
           with other cancer therapies in study participants with advanced GI malignancies.&#xD;
&#xD;
        -  To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007&#xD;
           administered in combination with other cancer therapies.&#xD;
&#xD;
        -  To evaluate the antitumor activity of ERAS-007 in combination with other cancer&#xD;
           therapies.&#xD;
&#xD;
        -  To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in&#xD;
           combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open-label, multicenter clinical study evaluating ERAS-007 in&#xD;
      combination with other cancer therapies in study participants with GI malignancies. This&#xD;
      study will serve as a platform study, allowing for evaluation of safety/tolerability and&#xD;
      efficacy of ERAS-007 in combination with other cancer therapies. The study will initially&#xD;
      commence with dose escalation of ERAS-007 administered in combination with encorafenib and&#xD;
      cetuximab in study participants with metastatic colorectal cancer (CRC) harboring B-Raf&#xD;
      proto-oncogene, serine/threonine kinase (BRAF) V600E mutation; and dose escalation of&#xD;
      ERAS-007 administered in combination with palbociclib in study participants with metastatic&#xD;
      CRC harboring Kirsten rat sarcoma (KRAS) or neuroblastoma rat sarcoma (NRAS) mutations. Dose&#xD;
      expansion will follow and will test ERAS-007 administered at the RD identified from each dose&#xD;
      escalation arm in study participants with metastatic CRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on adverse events observed during dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on adverse events observed during dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Dose (RD)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on adverse events observed during dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Incidence and severity of treatment-emergent AEs and serious AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (Cmax)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Maximum plasma or serum concentration of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Cmax (Tmax)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Time to achieve maximum plasma or serum concentration of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Area under the plasma concentration-time curve of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Half-life of ERAS-007 and other cancer therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 will be orally administered in combination with encorafenib and cetuximab to study participants with BRAFm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Part 2): ERAS-007 in combination with palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 will be orally administered in combination with palbociclib to study participants with KRASm or NRASm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 3): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with encorafenib and cetuximab to study participants with BRAFm CRC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 4): ERAS-007 in combination with palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 will be orally administered at the recommended dose (as determined from Part 2) in combination with palbociclib to study participants with KRASm or NRASm CRC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERAS-007</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <arm_group_label>Dose Escalation (Part 2): ERAS-007 in combination with palbociclib</arm_group_label>
    <arm_group_label>Dose Expansion (Part 3): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <arm_group_label>Dose Expansion (Part 4): ERAS-007 in combination with palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <arm_group_label>Dose Expansion (Part 3): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <other_name>Braftovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Administered via intravenous infusion</description>
    <arm_group_label>Dose Escalation (Part 1): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <arm_group_label>Dose Expansion (Part 3): ERAS-007 in combination with encorafenib and cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation (Part 2): ERAS-007 in combination with palbociclib</arm_group_label>
    <arm_group_label>Dose Expansion (Part 4): ERAS-007 in combination with palbociclib</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Willing and able to give written informed consent.&#xD;
&#xD;
          -  Have histologically or cytologically confirmed metastatic CRC harboring applicable&#xD;
             mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) based on an analytically&#xD;
             validated assay performed on tumor tissue in a certified testing laboratory.&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  Adequate bone marrow and organ function.&#xD;
&#xD;
          -  Have ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Willing to comply with all protocol-required visits, assessments, and procedures.&#xD;
&#xD;
          -  Able to swallow oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with a RAS, MEK, or ERK inhibitor. Depending on which treatment arm the&#xD;
             patient is assigned, other therapies could also be prohibitive.&#xD;
&#xD;
          -  Anti-cancer therapy ≤ 21 days or 4 half-lives prior to first dose of study drug,&#xD;
             whichever is shorter.&#xD;
&#xD;
          -  Palliative radiation ≤ 7 days prior to first dose of study drug.&#xD;
&#xD;
          -  Symptomatic brain metastasis or leptomeningeal disease.&#xD;
&#xD;
          -  Gastrointestinal conditions that may affect absorption of oral medications&#xD;
&#xD;
          -  Active infection requiring systemic therapy, or history of HIV infection, hepatitis B&#xD;
             virus, or hepatitis C virus.&#xD;
&#xD;
          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical&#xD;
             intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12&#xD;
             months prior to first study drug dose.&#xD;
&#xD;
          -  Active, clinically significant interstitial lung disease or pneumonitis.&#xD;
&#xD;
          -  Impaired cardiovascular function or clinically significant cardiovascular disease.&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events ≤ 6 months prior to first dose.&#xD;
&#xD;
          -  Major surgery within 28 days of enrollment, or anticipation of major surgery during&#xD;
             study treatment.&#xD;
&#xD;
          -  Known intolerance or contraindication to encorafenib, cetuximab, or palbociclib.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease or evidence of any other&#xD;
             significant clinical disorder or laboratory finding that renders the patient&#xD;
             inappropriate to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Komatsubara, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Senior Medical Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erasca Clinical Team</last_name>
    <phone>+1-858-465-6511</phone>
    <email>clinicaltrials@erasca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAF</keyword>
  <keyword>V600E</keyword>
  <keyword>KRAS</keyword>
  <keyword>NRAS</keyword>
  <keyword>mutation</keyword>
  <keyword>Braftovi</keyword>
  <keyword>encorafenib</keyword>
  <keyword>Erbitux</keyword>
  <keyword>cetuximab</keyword>
  <keyword>Ibrance</keyword>
  <keyword>palbociclib</keyword>
  <keyword>ERK</keyword>
  <keyword>MAPK</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>CRC</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>EGFR</keyword>
  <keyword>GI neoplasm</keyword>
  <keyword>gastrointestinal neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

